Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 12/20 | 0.46 |
| ▸ | MMP9 | P14780 | 11/20 | 0.46 |
| ▸ | MMP3 | P08254 | 10/20 | 0.46 |
| ▸ | MMP13 | P45452 | 10/20 | 0.46 |
| ▸ | MMP1 | P03956 | 9/20 | 0.46 |
| ▸ | MMP7 | P09237 | 9/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612792 | 0.84 | KDM4E (0.49) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL5839741 | 0.79 | KDM4E (0.49) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL5839738 | 0.79 | KDM4E (0.49) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL9115909 | 0.77 | KDM4E (0.47) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL7477404 | 0.77 | MMP2 (0.47) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL7477399 | 0.77 | MMP2 (0.47) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL13612447 | 0.76 | ADAMTS4 (0.43) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL9188981 | 0.76 | CA12 (0.50) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL9188977 | 0.76 | CA12 (0.50) | KDM4EMMP2MMP9MMP3MMP13 | |
| SCHEMBL6341063 | 0.76 | KDM4E (0.46) | KDM4EMMP2MMP9MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | SRR, EPHX2, ALOX5 | KDM4E 4509/4885MMP2 3701/4885MMP9 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.